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Abstract 
Background: In the UK, the solidaristic character of the NHS makes it one of the most trusted public institutions. In 
recent years, the introduction of data-driven technologies in healthcare has opened up the space for collaborations 
with private digital companies seeking access to patient data. However, these collaborations appear to challenge the 
public’s trust in the.
Main text: In this paper we explore how the opening of the healthcare sector to private digital companies chal-
lenges the existing social contract and the NHS’s solidaristic character, and impacts on public trust. We start by criti-
cally discussing different examples of partnerships between the NHS and private companies that collect and use data. 
We then analyse the relationship between trust and solidarity, and investigate how this relationship changes in the 
context of digital companies entering the healthcare system. Finally, we show ways for the NHS to maintain public 
trust by putting in place a solidarity grounded partnership model with companies seeking to access patient data. 
Such a model would need to serve collective interests through, for example, securing preferential access to goods 
and services, providing health benefits, and monitoring data access.
Conclusion: A solidarity grounded partnership model will help establish a social contract or licence that responds to 
the public’s expectations and to principles of a
solidaristic healthcare system.
Keywords: Solidarity, Solidaristic healthcare system, Public trust, Data sharing, Private companies, Data-driven 
technologies
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Background
The National Health Services (NHS) UK is a solidarity-
based institution, founded on the principles that: (1) all 
should contribute to it according to their means (through 
taxation); (2) all should be offered best care according to 
their needs; and (3) services should be free for all at the 
point of access. These foundational principles have made 
the NHS one of the most trusted institutions in the UK 
[1]. In recent decades, and particularly since the 1990s, 
private companies have been entering the care provi-
sion domain in the UK. Lately, partnerships between the 
public healthcare provider and private companies have 
intensified. Reasons for this closer collaboration between 
the two sectors is the increasing reliance of medicine 
and healthcare on new data-driven technologies, such 
as genomics medicine and artificial intelligence, but also 
the recognition of the financial value of NHS data to the 
international digital market [2]. With an ageing popula-
tion and after years of austerity, the NHS is struggling 
to meet the care needs of the population. Data-based 
technological solutions, such as artificial intelligence 
applications, have been proposed as a way of effectively 
responding to the funding and staffing crisis faced by the 
NHS [3], which has opened the door to private digital 
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companies developing such tools. The government has 
realised that the NHS, as the single largest integrated 
health care provider in the world, is in a unique position 
to attract ‘investments across the health tech and phar-
maceutical sector’ [4]. Since 2018, the two governmental 
industrial strategy deals centred on data-driven technolo-
gies to create and grow new industries in the UK, and on 
collaborations between the life sciences sector and indus-
try, universities and charities to demonstrate the value of 
the NHS as a partner in this new industrial vision [4].
The use of NHS data to drive economic growth rather 
than solely benefiting patients, is challenging the soli-
daristic character of the healthcare system. In 2018, the 
Secretary of State for Health and Social Care pleaded for 
a more tech- and big data-driven NHS, but also acknowl-
edged the importance of building and maintaining pub-
lic trust in the healthcare system [5]. And yet, there is 
increasing concerns regarding the use of patient data, and 
the motivations of private companies partnering with the 
NHS that appear contrary to public interest [6]. In light 
of the changes introduced by the use of data sciences in 
healthcare, some scholars have called for the need of a 
new ‘social contract’ [7] or ‘social licence’ [8] between the 
healthcare system, patients and society as a whole.
In this paper we explore how the opening of the health-
care sector to private digital companies challenge the 
existing social contract and the NHS’s solidaristic char-
acter, and how this impacts on public trust. We start by 
critically discussing different examples of partnerships 
between the NHS and private companies that collect 
and use data. We then analyse the relationship between 
trust and solidarity, and investigate how this relationship 
changes in the context of private companies entering the 
healthcare system. Finally, we propose ways for the NHS 
to maintain its solidaristic character and public trust by 
putting in place solidarity grounded partnerships with 
companies seeking to access patient data.
Methodology
This paper is a theoretical analysis arguing for the adop-
tion of solidarity grounded partnerships to govern data 
sharing between public healthcare systems and com-
mercial or private companies accessing patient data. Our 
analysis focuses on the UK context and draws on bioeth-
ics literature, surveys on public trust in health care and/
or data sharing, prominent case studies that gave rise to 
relevant debates in the UK, and official reports.
Discussion
NHS data mining and public trust
The delivery of a health service in the twenty-first cen-
tury increasingly relies on data. A number of data-driven 
technologies and applications are entering the space of 
healthcare, including genomics medicine and artificial 
intelligence (AI), promising more accurate prediction 
and prevention of disease, improved health outcomes 
and more efficient use of resources [9]. A vast array of 
clinical, genomic, demographic, environmental and 
social data are needed in order to fulfil these prom-
ises aiming to improve the performance and running of 
healthcare systems. Data has always been important for 
healthcare improvement. For a long time, however, only 
certain types of data, for example clinical, health records 
and clinical trial data, were considered to have direct 
health relevance. In recent years, and with the advance-
ment in big data science, a number of seemingly irrele-
vant and unrelated information have become important, 
as they can provide valuable insights into the health and 
health-related behaviour of individuals and populations. 
For example, people’s online behaviour could provide 
important information about the spread of infectious dis-
eases such as flu [10]. This growing utility and relevance 
of different types of data for health, has opened up the 
field of healthcare to types of companies and institutions 
that were not part of the healthcare landscape before, 
and created the conditions for collaboration between the 
public healthcare sector and commercial entities, such as 
digital companies (e.g. Google) and online retailers (e.g. 
Amazon).
One of the major holders of health-related data in the 
UK is the NHS. As the main healthcare provider, the 
NHS keeps a vast number of different types of data, from 
general practitioners’ notes, to clinical test results, to 
genetic and genomic information. These data, protected 
by the principle of confidentiality, traditionally stayed 
within the boundaries of the healthcare system [11, 12]. 
Identifiable patient information has only been used for 
the direct benefit of the patients. Anonymised patient 
data have been used by the NHS to improve care provi-
sion too; for example, hospital episode statistics have 
been collected and analysed by the NHS since 1989 [13]. 
Yet, in recent years, with the recognition of the health but 
also economic value NHS data hold, and with the expan-
sion of the healthcare space to non-traditional stakehold-
ers (e.g. digital companies), new projects and practices 
regarding data collection, use and sharing are emerging.
In 2013, the UK government tried to expand the NHS 
data sharing practice, by introducing a new scheme called 
care.data [14]. This new scheme aimed to bring together 
health and social care data from across the NHS, and 
share them, under strict conditions protecting patient 
privacy, with academic and commercial researchers to 
develop new treatments and improve the performance 
of the healthcare system. Some of the aims of care.data 
were to support patient choice, promote transparency, 
improve outcomes for patients, and also drive economic 
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growth [8]. Within a few months of the announcement 
of the new scheme, however, more than a million of 
patients opted-out of the care.data system, and by 2016, 
the scheme was discontinued [15]. The main reasons that 
led to the collapse of the care.data scheme was the lack 
of communication of the government’s plans and inten-
tions to the general public, and the people’s concern that 
NHS data will be shared with private commercial compa-
nies. In 2016, the Wellcome Trust published a report on 
a study regarding people’s attitudes to health data sharing 
with commercial actors. The study found that whereas 
the vast majority of the population was willing to share 
their data within the NHS and for non-commercial 
research, for many, sharing data with commercial com-
panies solely for private benefit and without clear public 
benefit constituted a ‘red line’ that should not be crossed 
[16]. In their analysis of the care.data case, Carter et  al. 
[8] observe that the scheme ‘failed to adequately secure 
a social licence’ i.e. society’s agreement, because of: (1) 
defects in the warrants of trust provided for care.data, (2) 
the implied rupture in the traditional role, expectations 
and duties of general practitioners, and (3) uncertainty 
about the status of care.data as a public good’. Such a 
social licence, the authors argue, is needed when a public 
and private body’s activities go ‘‘beyond compliance’ with 
legal requirements’ [8].
Around the same time of the care.data scheme, the 
UK Government announced another initiative aim-
ing at collecting patient data to support individualised 
care, medical innovation and economic development. In 
2013, Genomics England, a company owned by the UK 
Department of Health, was set up to oversee the 100,000 
Genomes Project, a UK Government initiative [17]. The 
aim of this initiative was to sequence 100,000 genomes, 
and to use the data generated for medical and scientific 
research. The original focus of the project was on rare 
diseases, infectious diseases, and some types of cancer. 
After meeting its primary target of 100,000 genomes, in 
2018, the project expanded its remit, aiming to sequence 
five million genomes over the following five years. As the 
success of the project heavily relied on patients’ willing-
ness to donate their data, the Chief Executive of Genom-
ics England acknowledged that ‘building trust in this 
exciting and revolutionary area of medical science is 
absolutely essential to its success’ [18]. The project set 
up an independent ethics committee and endeavoured 
right from the beginning for greater transparency, public 
involvement and also technological solutions to address 
data security concerns as a way of ensuring public trust. 
In 2019, Genomics England published a report on public 
views on the use and sharing of genomic data [19]. Whilst 
survey participants expressed their support of the over-
all initiative, once again, one of their main concerns was 
the involvement of private companies and the sharing of 
data with private institutions that did not seem to share 
the solidaristic ethos of the NHS. Participants seemed 
to trust the NHS to use their data for the common good, 
but their trust did not extend to include other actors that 
might be given access to their information. The report 
recommended that public trust can only be built and 
maintained if the NHS keeps embodying its core values 
of reciprocity, altruism, and solidarity.
Despite the failure of care.data, and people’s concerns 
about the increasing access private companies are given 
to patient information, the government continued with 
its plans to extract value from NHS data. In 2016, the 
NHS agreed a deal with DeepMind, an AI company, to 
access sensitive data of more than one million patients. 
DeepMind was later acquired by Google, and in 2019, 
five NHS Trusts (legal entities providing hospital ser-
vices, community services and/or other aspects of patient 
care) agreed data access contracts with Google Health 
[20]. In 2019, there was a similar deal with Amazon 
where the technological company was given free access 
to NHS patient data in order to develop the Amazon 
Alexa health device that can offer health advice to its cus-
tomers [21]. Subsequently, the government that signed 
the contract has been heavily criticised, among others by 
privacy organisations, for lacking transparency and pri-
oritising commercial interest [22].
The public’s concern with and apprehension regarding 
the sharing of their health data with bodies outside the 
NHS, and particularly with commercial entities is well 
documented [6, 16, 18]. However, the digital revolution 
that the UK Government is envisaging and promoting for 
cutting-edge healthcare depends on the public’s co-oper-
ation and continuing trust in the NHS and other relevant 
institutions [5]. Yet, in the emerging healthcare landscape 
that involves collaborators that do not seem to share the 
solidaristic core values of the NHS, maintaining public 
trust appears increasingly challenging.
Solidarity and public trust in the healthcare system
Solidarity is the founding principle of publicly funded 
healthcare systems, and has occupied an important place 
in the development of healthcare policies in Europe, since 
the late nineteenth century [23]. In public healthcare sys-
tems, access to services and care is organised by the gov-
ernment and funded through either mandatory payments 
of an insurance premium (e.g. in Germany, France and 
Belgium) or taxation (e.g. in the UK and Canada). As ter 
Meulen argues, individuals accept state enforced solidar-
ity for two reasons: on the one hand out of ‘self-interest’ 
and on the other hand out of ‘a feeling of responsibility 
[…] togetherness and commitment to the common good’ 
[24]. It is this collective sense of social cohesion and 
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interdependence what distinguishes publically funded 
from private healthcare systems [25].
Although solidarity has never been a widely used 
notion in the political and social discourse in the UK 
[26], the NHS’s founding principles of universality, equity, 
comprehensiveness, quality, free services, and public 
funding [27], have laid the ground for a healthcare sys-
tem that distributes resources and free care based on 
need rather than ability to pay. In this way, the NHS as 
a public institution is demonstrating its commitment to 
the common good, and is promoting a sense of mutual 
responsibility, which are central to the concept of solidar-
ity [28]. Solidarity has two meanings; one descriptive and 
one normative. First, and this goes back to Durkheim, 
solidarity describes the social bond that ties individuals 
together through acknowledgement of reciprocity and 
interdependence [29]. Second, this bond or feeling of 
social cohesion implies that members of a group have a 
set of normative expectations of what they owe to each 
other, that is how to behave in a solidaristic way [30]. 
What distinguishes solidarity from other related con-
cepts such as justice or altruism, is its relational aspects 
that makes individuals identify with each other and ‘stand 
up for/with/as’ to promote joint interests [31].
The expectation of solidarity and the lived experi-
ence of it can promote public trust in social institutions. 
According to Uslaner, trusting societies are the ones that 
share resources equally amongst their members [32]. 
Similarly, Rothstein and Stolle argue that solidaristic 
welfare programmes that do not differentiate between 
individuals (e.g. selective welfare programmes) but are 
universal in coverage contribute to the development and 
establishment of trust between society members [33]. 
Thus, public trust is built on the reasonable belief that 
public institutions will serve the common good and rep-
resent collective interests [34]. This is supported by a col-
lective feeling of commonality and mutuality reinforced 
by institutional structures and public policies.
One example of the relationship between public trust 
and solidarity is the NHS. Since its foundation, and 
despite a general decrease of trust in public institutions 
among Britons [1], the NHS has been, and still is, one of 
the most appreciated and respected public institutions 
in the UK [35, 36].Years of underfunding, which led to 
a decrease and underperformance of its services, have 
fuelled concerns amongst the population of whether the 
NHS can be maintained in its current form [37]. A survey 
of 2017 showed that a large majority of the population 
(around 90%) are concerned about the NHS maintaining 
its foundational principles such as that the NHS should 
be free at the point of delivery, provide a comprehensive 
service available to everyone, and be primarily funded 
through taxation [37, 38]. More than half of the survey 
respondents indicated that they are willing to support 
the NHS and its ability to provide good quality care for 
all through solidaristic measures such as increased taxa-
tion [38]. This shows that it is not only the reliance on the 
NHS’s skills and ability to provide good care that drives 
public trust, but also its solidaristic character as an indi-
cation of the NHS’s moral attitude of good will towards 
those in need of care [39].
Despite the wide support among the population for 
a healthcare system that is committed to the common 
good and promotes mutual responsibility, for example, 
through taxation, the UK governments since 2010 have 
sought to resolve the NHS funding problem mainly 
through partnerships with commercial entities such as 
those seeking access to patient data. These partnerships 
with profit-oriented collaborators appear to contradict 
the solidaristic character of the NHS that is based on 
accepting mutual responsibility, recognising the impor-
tance of the community, and on developing feelings of 
togetherness. People’s concern and discontent regarding 
these developments are expressed in the form of mistrust 
towards the government and its new profit-driven part-
ners. As described above, these partnerships often lack 
transparency and a ‘social licence’ to operate outside of 
the ‘societal seal of approval’. As Carter et al. put it, public 
trust and a social licence can only be gained when ‘rea-
sonable citizens can […] recognise [an activity, such as 
data sharing] as defensible on the grounds that it reflects 
common social values and goals’ [8]. Yet these values 
and goals are put into question by the new partnerships 
between the NHS and commercial bodies. The question 
arises then as to if, and if so how, the NHS can maintain 
its solidaristic character and hence, public trust regarding 
data sharing, when more and more commercial interests 
enter the public healthcare sector.
Maintaining solidarity and public trust in a cash‑strapped 
NHS
It appears that in order for people to maintain their 
trust in the NHS and agree to their data to be used for 
purposes beyond direct health benefit including (aca-
demic and commercial) research and economic benefit, 
the NHS needs to uphold its solidaristic character. As 
outlined above, this seems increasingly challenging in a 
cash-strapped healthcare system, with more and more 
private companies entering the field, diluting its public 
character. Should partnerships with commercial entities 
be avoided altogether? Considering the potential of data-
driven technologies to improve and personalise patient 
care and the fundamental role private companies play in 
developing such technologies, this would seem, at least at 
this stage, unreasonable. Is it possible, then, for both the 
NHS and private digital companies that seek access to its 
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data (e.g. Google, Amazon) to build trustworthy partner-
ships, and if so how? And, what would the social contract 
or licence1 that is the ‘common set of principles and val-
ues that bind together’ [7] the NHS and society look like 
in this new context?
As a minimum criterion, partnerships between the 
NHS and the private sector will need to be arranged in 
a way that preserve public trust and maintain the health-
care system’s solidaristic character [40]. This means that 
these partnerships will need to reflect in their structure, 
organisation and stated aims the basic principles of uni-
versality, equality and quality. The introduction of laws 
and regulations can go some way to convince people that 
their interests are protected. However, as Shapiro notes, 
trust often appears to have a paradoxically reverse rela-
tionship to laws and regulations; the more fidelity assur-
ances one seeks through laws and regulations, the less 
trustworthy these assurances appear [41]. The pursuit of 
collective interests and the common good seems crucial 
to the establishment and preservation of trust [34] that 
needs to sit alongside strict regulations as offered by e.g. 
the EU General Data Protection Regulation [42] or the 
Big Data Task Force of European Medicines Agencies 
and the Heads of Medicines Agencies [43]. Yet, regula-
tions, unless strictly and consistently enforced, can be 
neglected or overlooked by individual actors. As Carter 
et al. observe, trust in data use does not depend on, for 
example, the ‘formal architecture of research regulation, 
or on rational assessment of the detail of information 
sheets or other documents aimed at gaining ‘informed 
consent’’ [8]. Rather, trust in the use of their data by com-
mercial companies developing new tools relies ‘heavily 
on its status as a socially valuable enterprise conducted in 
the service of the public good’.
However, a selfless commitment to the public good 
might appear to be at odds with the interests of profit-
oriented private companies partnering with the NHS. Is 
it, therefore, reasonable to suggest that these partner-
ships could be founded on public benefit rather than 
shareholders’ profit? Governance arrangements that 
place the common good at the core of the partnership 
could offer an acceptable approach to this. When design-
ing and negotiating partnerships and collaborations with 
private and commercial companies, NHS officials and 
the government should build these on norms of solidar-
ity and public benefit and also take note of the various 
suggestions included in the published reports on public 
views and expectations regarding the use of patient data, 
and also where its ‘red lines’ lie. This would provide them 
not only with a useful insight but also a roadmap to draft 
arrangements that foster the social contract or licence 
with the public, convince them of their commitment to 
solidaristic principles and maintain trust. Following these 
recommendations, the NHS could: (1) require preferen-
tial access to goods and services developed using its data 
[6]; (2) require that data are used only to improve health 
and healthcare and not to serve the interests of private 
insurance companies or other commercial interests [18, 
44]; (3) conflicts of interests partners might have are pub-
licly declared, managed and resolved; (4) use a monitored 
data-visiting model of access similar to the one developed 
by Genomics England, rather than a data-sharing model 
where the data leaves the NHS custodianship. The NHS 
national data opt-out policy argues that giving patients 
more say and active control over their own data could 
preserve public trust in the healthcare system [45]. Not-
withstanding the importance of allowing individuals the 
option to express their own preferences and values that 
an opt-out system presents, placing too much emphasis 
on the responsibility of the individual to take active con-
trol over their data seems at odds with the basic charac-
teristics of solidarity and public trust. Firstly, requiring 
patients to take individual responsibility for the use of 
their data implies a relationship of mistrust rather than 
trust. Requiring individual to protect their own interests 
could be perceived as the system’s inability or reluctance 
to fulfil its role of acting in the public’s best interest. Sec-
ondly, by relying on people to take control of their own 
data, the system might end up undermining the public 
good it is tasked with serving. Rather, it becomes a man-
ager of individual preferences, thus losing its solidaristic 
characteristics of universality and equality. Thirdly, by 
inviting people to think and act as individuals protecting 
their own interests, the feelings of mutuality and com-
monality, foundational for solidarity, get weakened and 
the bond between society members might be lost [25].
If the NHS is to remain the most supported and trusted 
institution in the UK, using data-driven technologies to 
provide more accurate prediction and prevention of dis-
ease, improve health outcomes and more efficient use of 
resources, it will need to retain its foundational princi-
ple of serving the public good, and promote the beliefs 
of mutuality and commonality in society. Only if it can 
prove its continuous solidaristic character, the NHS will 
succeed in maintaining public trust and in negotiating a 
new social contract or licence.
1 Both terms describe a set of values and norms defining responsibilities and 
rights that are im-/explicitly ‘agreed upon’ in a society. Whereas the social 
licence focuses more on procedural agreements, the term social contract 
refers to the ‘broader context of social arrangements, practices and institu-
tions’ (7.Lucassen A, Montgomery J, Parker M. Chapter  16. Ethics and the 
social contract for genomics in the NHS. Annual Report of the Chief Medical 
Officer 2016: Department of Health; 2017.).
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Conclusion
People trusts solidaristic institutions that openly pre-
serve collective interests, and promote collective well-
being. In the UK, the solidaristic character of the NHS 
makes it one of the most trusted public institutions. 
In recent years, however, public trust has been chal-
lenged due to private companies collaborating with 
the NHS and been given access to its patient data. 
Despite the potential benefits of data-driven health-
care (e.g. more accurate prediction and prevention of 
disease, improved health outcomes and more efficient 
use of resources), partnerships with profit-oriented 
companies do not necessarily chime with the NHS’s 
foundational principles of universality and equity. Con-
sequently, trust in the NHS is put to the test.
In order to, nevertheless, maintain public trust without 
forgoing the potential benefits of data-driven healthcare 
technologies, the NHS needs to put in place solidarity 
grounded partnerships with companies seeking to access 
patient data. Such partnerships would need to serve col-
lective interests through, for example, securing pref-
erential access to goods and services, providing health 
benefits, and monitoring data access. This approach will 
help establish a social contract or licence that responds 
to expectations and principles of a solidaristic healthcare 
system. As the current health minister rightly observed, 
unless the NHS maintains public trust, the vision of a 
data-driven healthcare will not be realisable.
Although our analysis focuses on the UK context, it 
contributes to the wider bioethics discussion regarding 
the governance of data sharing between public health-
care systems and commercial companies.
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